These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35316080)

  • 1. Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study.
    Bridgewater J; Fletcher P; Palmer DH; Malik HZ; Prasad R; Mirza D; Anthony A; Corrie P; Falk S; Finch-Jones M; Wasan H; Ross P; Wall L; Wadsley J; Evans TR; Stocken D; Stubbs C; Praseedom R; Ma YT; Davidson B; Neoptolemos J; Iveson T; Cunningham D; Garden OJ; Valle JW; Primrose J;
    J Clin Oncol; 2022 Jun; 40(18):2048-2057. PubMed ID: 35316080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.
    Primrose JN; Fox RP; Palmer DH; Malik HZ; Prasad R; Mirza D; Anthony A; Corrie P; Falk S; Finch-Jones M; Wasan H; Ross P; Wall L; Wadsley J; Evans JTR; Stocken D; Praseedom R; Ma YT; Davidson B; Neoptolemos JP; Iveson T; Raftery J; Zhu S; Cunningham D; Garden OJ; Stubbs C; Valle JW; Bridgewater J;
    Lancet Oncol; 2019 May; 20(5):663-673. PubMed ID: 30922733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current standards and future perspectives in adjuvant treatment for biliary tract cancers.
    Lamarca A; Edeline J; McNamara MG; Hubner RA; Nagino M; Bridgewater J; Primrose J; Valle JW
    Cancer Treat Rev; 2020 Mar; 84():101936. PubMed ID: 31986437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care.
    Rizzo A; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):483-485. PubMed ID: 33307876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
    de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM
    Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions.
    Rizzo A; Brandi G
    Cancer Treat Res Commun; 2021; 27():100334. PubMed ID: 33592563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
    Noh SH; Park SR; Yang HK; Chung HC; Chung IJ; Kim SW; Kim HH; Choi JH; Kim HK; Yu W; Lee JI; Shin DB; Ji J; Chen JS; Lim Y; Ha S; Bang YJ;
    Lancet Oncol; 2014 Nov; 15(12):1389-96. PubMed ID: 25439693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Network meta-analysis of adjuvant chemotherapy in biliary tract cancers: Setting the scene for new randomized evidence.
    Salani F; Vetere G; Rossini D; Genovesi V; Carullo M; Bartalini L; Massa V; Bernardini L; Caccese M; Cesario S; Graziani J; Grelli G; Mangogna F; Vivaldi C; Masi G; Fornaro L
    Liver Int; 2024 Oct; 44(10):2763-2772. PubMed ID: 39072988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives.
    Akhoundova Sanoyan D; McNamara MG; Lamarca A; Valle JW
    Curr Opin Oncol; 2020 Jul; 32(4):364-369. PubMed ID: 32541326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
    Cameron D; Morden JP; Canney P; Velikova G; Coleman R; Bartlett J; Agrawal R; Banerji J; Bertelli G; Bloomfield D; Brunt AM; Earl H; Ellis P; Gaunt C; Gillman A; Hearfield N; Laing R; Murray N; Couper N; Stein RC; Verrill M; Wardley A; Barrett-Lee P; Bliss JM;
    Lancet Oncol; 2017 Jul; 18(7):929-945. PubMed ID: 28600210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant Chemotherapy and Outcomes in Older Adult Patients With Biliary Tract Cancer.
    Gbolahan OB; Zhi X; Liu Y; Shah MM; Kooby DA; Alese OB
    JAMA Netw Open; 2024 Jan; 7(1):e2351502. PubMed ID: 38206623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Bang YJ; Kim YW; Yang HK; Chung HC; Park YK; Lee KH; Lee KW; Kim YH; Noh SI; Cho JY; Mok YJ; Kim YH; Ji J; Yeh TS; Button P; Sirzén F; Noh SH;
    Lancet; 2012 Jan; 379(9813):315-21. PubMed ID: 22226517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capecitabine Extends Survival for Biliary Tract Cancer.
    Cancer Discov; 2017 Jul; 7(7):OF1. PubMed ID: 28572460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract.
    Graham JS; Boyd K; Coxon FY; Wall LR; Eatock MM; Maughan TS; Highley M; Soulis E; Harden S; Bützberger-Zimmerli P; Evans TR
    BMC Res Notes; 2016 Mar; 9():161. PubMed ID: 26969121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol.
    Cheng X; Wu D; Xu N; Chen L; Yan Z; Chen P; Zhou L; Yu J; Cui J; Li W; Wang C; Feng W; Wei Y; Yu P; Du Y; Ying J; Xu Z; Yang L; Zhang Y
    BMC Cancer; 2021 Jan; 21(1):56. PubMed ID: 33435909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
    Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
    Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study.
    Siebenhüner AR; Seifert H; Bachmann H; Seifert B; Winder T; Feilchenfeldt J; Breitenstein S; Clavien PA; Stupp R; Knuth A; Pestalozzi B; Samaras P
    BMC Cancer; 2018 Jan; 18(1):72. PubMed ID: 29325521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer.
    Rizzo A; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):547-554. PubMed ID: 33571059
    [No Abstract]   [Full Text] [Related]  

  • 19. A systematic review and network meta-analysis of adjuvant therapy for curatively resected biliary tract cancers.
    Kish M; Chan K; Perry K; Ko YJ
    Curr Oncol; 2020 Feb; 27(1):e20-e26. PubMed ID: 32218664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.
    Chen YP; Liu X; Zhou Q; Yang KY; Jin F; Zhu XD; Shi M; Hu GQ; Hu WH; Sun Y; Wu HF; Wu H; Lin Q; Wang H; Tian Y; Zhang N; Wang XC; Shen LF; Liu ZZ; Huang J; Luo XL; Li L; Zang J; Mei Q; Zheng BM; Yue D; Xu J; Wu SG; Shi YX; Mao YP; Chen L; Li WF; Zhou GQ; Sun R; Guo R; Zhang Y; Xu C; Lv JW; Guo Y; Feng HX; Tang LL; Xie FY; Sun Y; Ma J
    Lancet; 2021 Jul; 398(10297):303-313. PubMed ID: 34111416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.